1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Here’s the deal.....

Discussion in 'Dermira' started by anonymous, Nov 17, 2018 at 4:01 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    We are either going to buy a few products to add some revenue to this company. Or, we will be sold before the AD drug is approved so the executives can cash out! Wipes just won’t cut!
     

  2. anonymous

    anonymous Guest

    You’re right, Dermira missed their sales target for the third quarter. The stock is below prelaunch. Maybe leadership should take a good hard look at why so many reps were hired who had no previous dermatology experience when so many with several years of dermatology experience and relationships were passed over. Some didn’t even get an interview with the hiring manager. The reps with prior dermatology experience could have hit the ground running building sales instead of introducing themselves. I would take a real hard look at the incompetence of leadership. It was such a “no brainer”.
     
  3. anonymous

    anonymous Guest

    Sounds like an idiot posting here. Dermira missed their sales target for Q3? Yeah, cause that makes total sense.... the drug launched October 1st you dumbass, no sales target was measured for Q3.

    Before you get on here and post the stupidest shit get your facts straight you miserable maggot.
     
  4. anonymous

    anonymous Guest

    They did hire the wrong personnel in many cases. Those interviews were so big pharma tactics. This is derm!!! It’s relationship selling. You have a wipe for hyperhidrosis. Give me a break.
     
  5. anonymous

    anonymous Guest

    Just look at all the bad long term care hires in Texas including management. Such a joke. Poor business decisions from top down.
     
  6. anonymous

    anonymous Guest

    Texas is killin’ it, yo.
     
  7. anonymous

    anonymous Guest

    What’s worse is that somone actually thinks that one needs ‘derm’ experience to be successful. Of all the ‘Derm’ reps out there, more than half are average or worse. Look at what it takes to create demand and work hard to drive business. Derm experience is an insult. A crappy product may also be a possible answer to lackluster sales.
     
  8. anonymous

    anonymous Guest

    relationships get you into doors and open ones that would be closed to a new rep!
    You really are a special kind of stupid!
    Shit products can move if the doctor respects the rep! It’s been proven time and time again! The above comment was spoken like a clueless puppet of a manager.
     
  9. anonymous

    anonymous Guest

    Amature hour leadership team not to mention the home office jokers.
     
  10. anonymous

    anonymous Guest

    Stock is tanking, options are worthless, nobody is prescribing. Time to move on
     
  11. anonymous

    anonymous Guest

    Wow, this is $6. All time low...that aint good
     
  12. anonymous

    anonymous Guest

    Yes this is a dead end job, stock is in the toilet and there is no way in hell our leadership is experienced enough to get us out of this s-show.
     
  13. anonymous

    anonymous Guest

    Our sales leaders should stick to playing instruments at meetings, they are better suited for that than leading!
     
  14. anonymous

    anonymous Guest

    Is there any reason for the stock to move? No. Biotech stocks tanked in Q4 for the most part, look at Aclaris, Evolus. If you knew what you signed up for here, you should know the stock isn’t going to move much until Lebri data gets posted ya dumbass.
     
  15. anonymous

    anonymous Guest

    This will see $4 before it sees $10
     
  16. anonymous

    anonymous Guest

    Lol!
     
  17. anonymous

    anonymous Guest

    Is the pit wipe kingdom collapsing already?
     
  18. anonymous

    anonymous Guest

    pretty much!
     
  19. anonymous

    anonymous Guest

    Dermira stock, closer to its 52 week low than it’s 52 week high after launching a new product! OUCH!
     
  20. anonymous

    anonymous Guest

    Managers are leaving and now reps. Just wait! Screw this place.